iBio, Inc.
IBIO
$1.04
-$0.03-2.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 500.00K | 400.00K | 375.00K | 375.00K | 175.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 500.00K | 400.00K | 375.00K | 375.00K | 175.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 500.00K | 400.00K | 375.00K | 375.00K | 175.00K |
| SG&A Expenses | 10.39M | 10.69M | 10.96M | 10.71M | 10.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.95M | 19.00M | 17.19M | 15.94M | 15.81M |
| Operating Income | -20.45M | -18.60M | -16.81M | -15.56M | -15.64M |
| Income Before Tax | -20.11M | -18.38M | -16.46M | -14.23M | -14.36M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.11 | -18.38 | -16.46 | -14.23 | -14.36 |
| Earnings from Discontinued Operations | -- | -- | -4.53M | -5.07M | -8.79M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.11M | -18.38M | -20.99M | -19.30M | -23.15M |
| EBIT | -20.45M | -18.60M | -16.81M | -15.56M | -15.64M |
| EBITDA | -19.67M | -17.83M | -16.02M | -14.71M | -14.75M |
| EPS Basic | -1.62 | -1.79 | -2.34 | -2.70 | -6.65 |
| Normalized Basic EPS | -1.01 | -1.12 | -1.13 | -1.44 | -2.65 |
| EPS Diluted | -1.62 | -1.79 | -2.34 | -2.70 | -6.65 |
| Normalized Diluted EPS | -1.01 | -1.12 | -1.13 | -1.44 | -2.65 |
| Average Basic Shares Outstanding | 53.05M | 42.02M | 36.21M | 30.06M | 22.79M |
| Average Diluted Shares Outstanding | 53.05M | 42.02M | 36.21M | 30.06M | 22.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |